Profile data is unavailable for this security.
About the company
Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. The Company's core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.
- Revenue in GBP (TTM)838.00k
- Net income in GBP-3.35m
- Incorporated2014
- Employees7.00
- LocationEvgen Pharma PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
- Phone+44 162 531 5090
- Websitehttps://evgen.com/
Mergers & acquisitions
| Acquired company | EVG:LSE since announced | Transaction value |
|---|---|---|
| Chronos Therapeutics Ltd | -18.42% | 4.33m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuformix PLC | 0.00 | -436.95k | 1.68m | 2.00 | -- | 0.3637 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| N4 Pharma PLC | 0.00 | -925.31k | 2.28m | 5.00 | -- | 1.37 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -59.56 | -58.71 | -65.34 | -63.61 | -- | -- | -- | -8,155.51 | -- | -1,910.05 | 0.00 | -- | -- | -- | 33.35 | -- | -- | -- |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn | 3.09m | 25.00 | -- | 3.90 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| Evgen Pharma PLC | 838.00k | -3.35m | 3.31m | 7.00 | -- | 0.5414 | -- | 3.95 | -0.0122 | -0.0122 | 0.0031 | 0.0143 | 0.1406 | -- | 1.81 | 119,714.30 | -56.25 | -42.37 | -60.57 | -46.32 | -- | -- | -400.12 | -2,324.84 | -- | -- | 0.00 | -- | -- | -- | -48.10 | -- | -32.24 | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.58m | 50.00 | -- | 1.53 | -- | 2.26 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 3.81m | 7.00 | -- | 1.72 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
| IXICO PLC | 6.67m | -1.18m | 4.23m | 89.00 | -- | 0.3701 | -- | 0.6348 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| ValiRx Plc | 0.00 | -2.41m | 4.57m | 8.00 | -- | 0.8397 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 4.75m | 4.00 | -- | 0.9783 | -- | 367.35 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.18m | 5.51m | 0.00 | -- | 2.68 | -- | -- | -0.004 | -0.004 | 0.00 | 0.0059 | 0.00 | -- | -- | -- | -48.01 | -- | -51.61 | -- | -- | -- | -- | -- | -- | -6,299.75 | 0.00 | -- | -- | -- | -35.13 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 05 Apr 2024 | 25.79m | 9.38% |
| Octopus Investments Ltd.as of 05 Apr 2024 | 21.88m | 7.96% |
| AXA Investment Managers UK Ltd.as of 27 Dec 2023 | 13.40m | 4.88% |
| Chelverton Asset Management Ltd.as of 05 Jun 2023 | 12.50m | 4.55% |
| RAB Capital Ltd. (Investment Management)as of 05 Jun 2023 | 8.75m | 3.18% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2023 | 7.77m | 2.83% |
| Jarvis Investment Management Ltd.as of 01 Jun 2023 | 4.55m | 1.65% |
| IG Markets Ltd.as of 01 Jun 2023 | 3.89m | 1.42% |
| Rowan Dartington & Co. Ltd. (Broker)as of 01 Jun 2023 | 3.69m | 1.34% |
| HSBC Bank Plc (Market-Maker)as of 01 Jun 2023 | 1.83m | 0.67% |
